Final US approval for Teva's generic Lexapro
Israel's Teva Pharmaceutical Industries says that the US Food and Drug Administration has granted final approval for its Abbreviated New Drug Application to market its generic version of Forest Laboratories' Lexapro (escitalopram oxalate) tablets, 5mg, 10mg and 20mg.
Teva's AB-rated escitalopram oxalate tablets are indicated for the treatment of depression.
Teva is currently in patent litigation concerning this product in the US District Court for the District of Delaware. A suit was brought against its subsidiary, IVAX, in September 2003 involving its paragraph IV certification to US Patent No RE34,712. A trial was held in March 2006 and the post-trial briefing period ended on May 19.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze